Stoke Therapeutics Stock Triggers Death Cross, Bearish Marubozu on 15-Minute Chart

Based on the analysis of Stoke Therapeutics's 15-minute chart, a KDJ Death Cross and Bearish Marubozu pattern was observed on October 10, 2025 at 15:45. This indicates that the momentum of the stock price is shifting towards the downside, and there is a potential for further decreases in value. The sellers are currently in control of the market, and the bearish momentum is likely to continue.

Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) recently presented new data at the 54th Child Neurology Society (CNS) Annual Meeting, supporting the potential of zorevunersen as a disease-modifying medicine for Dravet syndrome. The presentation highlighted long-term improvements in cognition and behavior, as well as overall clinical status, observed in patients treated with zorevunersen.

The companies presented two-year data from an analysis that evaluated the potential effects of the Phase 3 zorevunersen dosing regimen on cognition and behavior. These results showed continuing improvements at two years, contrasting with minimal changes observed in a natural history study of patients treated with standard care. Additionally, three-year results from analyses of Clinical and Caregiver Global Impression of Change (CGI-C and CaGI-C) scales measuring overall clinical status were presented. Caregivers and clinicians reported similar improvements in overall clinical status in 95% of patients treated with zorevunersen.

Dr. Kelly Knupp, Professor of Pediatrics and Neurology at the University of Colorado Anschutz and the Dravet Program Director and Epilepsy Program Lead at Children's Hospital Colorado, commented on the significance of these findings. "The natural history data continue to provide important context for the effects we are seeing in patients treated with zorevunersen. Improvements in cognition and behavior are not something we see in patients with Dravet syndrome, and rarely do we see such strong correlation between caregiver and clinician-reported outcomes. Together, these data are starting to paint a fuller picture of the potential impact disease modification could have on a patient’s overall health and daily living."

The data were part of a poster presentation that included results from the Phase 1/2a and ongoing open-label extension (OLE) studies of zorevunersen. Safety and tolerability were the primary endpoints of these studies, with effects on major motor seizure frequency, cognition, and behavior assessed as secondary endpoints. The studies showed substantial and durable reductions in major motor seizure frequency and improvements in multiple measures of cognition and behavior on top of a background of standard anti-seizure medicines through three years.

The most substantial reductions were observed among patients who were treated with loading doses of 70mg in the Phase 1/2a study followed by maintenance doses of 45mg. This regimen is now being evaluated in the Phase 3 EMPEROR study. Zorevunersen has been generally well tolerated across the studies, with study drug-related treatment emergent adverse events (TEAEs) observed in 30% (24/81) and 53% (40/75) of patients treated in the Phase 1/2a and OLE studies, respectively. The most common study drug-related TEAE was CSF protein elevations reported in 14% (11/81) and 44% (33/75) of patients in the Phase 1/2a and OLE studies, respectively. No related clinical manifestations have been observed, although one patient discontinued treatment due to elevated CSF protein levels.

The presentation was titled "Zorevunersen demonstrates disease-modifying potential in patients with Dravet syndrome through durable seizure reduction and continuing improvements in cognition, behavior, and functioning through 36 months of treatment in open-label extension studies" and was presented by Dr. Joseph Sullivan, M.D., FAES, Professor of Neurology and Pediatrics and Director of the Pediatric Epilepsy Center of Excellence at the University of California San Francisco.